P&G sells Sure
This article was originally published in The Rose Sheet
Executive Summary
Innovative Brands has completed the acquisition of the Sure antiperspirant and deodorant brand from Procter & Gamble, the division of Najafi Companies reports Sept. 26. "We will focus investments to increase awareness, create excitement, and build successful marketing relationships for this brand," the firm says, noting the range "can appeal to both the male and female segments of the market because of its quality performance attributes and simple fragrances." The acquisition is in line with the company's strategy of purchasing consumer brands that no longer fit the strategic direction of larger corporations. In July, Innovative Brands acquired Pert hair care brand from P&G (1"The Rose Sheet" July 17, 2006, In Brief)...
You may also be interested in...
P&G sells Pert
Procter & Gamble has sold its PertPlus hair care brand to private equity firm Najafi Companies in order to focus on core brands Aussie,Head & Shoulders, Herbal Essences,Infusium 23 and Pantene, according to the company. Phoenix, Ariz.-based Najafi will assume ownership of the brand in the U.S., Canada, Puerto Rico and the Caribbean; however, P&G will retain the rights to Pert Plus in Asia and Latin America. Pert Plus will be part of Najafi's Innovative Brands division, which plans to "grow and sustain the brand for the long term," Najafi states. "There are tremendous opportunities for growth and product expansion," Innovative Brands adds...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.